SSY Group Limited — Board/Management Information 2014

Dec 15, 2014

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [311 x 113] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

RESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “Board”) of the directors (the “Directors”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Mr. Su Xuejun has been appointed as the executive director of the Company with effect from 15 December 2014 and Mr. Duan Wei has been resigned as the executive director of the Company with effect from 15 December 2014.

Appointment of Mr. Su Xuejun (“Mr. Su”) as executive director

Mr. Su, aged 46, was appointed as the executive director of the Company. He is currently the executive director, deputy chairman and deputy general manager of Shijiazhuang No.4 Pharmaceutical Co., Ltd., responsible for the company's overall marketing and management. Mr. Su joined Shijiazhuang City No.1 Pharmaceutical Factory as assistant to factory manager in 1990. And afterwards he served as deputy general manager of a subsidiary of the Shijiazhuang Pharmaceutical Group selling preparations. Since January 2002, Mr. Su acts as deputy general manager of Shijiazhuang No.4 Pharmaceutical Co., Ltd. Since January 2007, Mr. Su acts as executive director of Shijiazhuang No.4 Pharmaceutical Co., Ltd. and New Orient Investments Pharmaceutical Holding (Hong Kong) Limited. Since July 2013, Mr. Su acts as deputy chairman of Shijiazhuang No.4 Pharmaceutical Co., Ltd. Su focuses in the pharmaceutical market development, operations and management. He has extensive understanding and experience in the marketing and the policy in the related industries. Mr. Su graduated from Hebei Normal University, majoring in biology, with a bachelor's degree.

Mr. Su’s nomination as an executive director is based on the recommendation from the Nomination Committee of the Company having regard to his expertise and experience.

Mr. Su has entered into a letter of appointment with the Company for a term of three years and he is subject to retirement by rotation and is eligible for re-election at the upcoming general meeting of the Company in accordance with the articles of association of the Company. Mr. Su is entitled to receive a director’s fee of HK$750,000 per annum which is determined with reference to his duties and responsibilities with the Company and the prevailing market condition.

1

Save as disclosed above, Mr. Su (i) does not hold any other position with the Company and other members of the Company and its subsidiaries; (ii) is not related to any directors, senior management, substantial or controlling shareholders of the Company; and (iii) has not held other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or other major appointments and professional qualifications.

As at the date of this announcement, Mr. Su does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Su has confirmed that there is no other information that is required to be disclosed in accordance with Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter relating to his appointment that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warmest welcome to Mr. Su for joining the Company.

Resignation of Mr. Duan Wei (“Mr. Duan”) as executive director

The Board of the Company announces that Mr. Duan has resigned as an executive director of the Company with effect from 15 December 2014 in order to devote more time to his other business engagements.

Mr. Duan has confirmed that there is no disagreement between him and the Board or the Company and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. The Board would like to take this opportunity to express its appreciation to Mr. Duan for his valuable contribution to the Company during his tenure of office as an executive director of the Company.

By Order of the Board Chan Ka Kit Company Secretary

Hong Kong, 15 December 2014

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

2